Science & Enterprise subscription

Follow us on Twitter

  • Covid-19 is truly a global pandemic, and today we offer a new map showing where the disease has spread.…
    about 18 hours ago
  • New post on Science and Enterprise: Infographic – Covid-19 Global Spread Near Complete #Science #Business
    about 18 hours ago
  • University engineering and medical groups designed simple, open-source face shields for health care workers on the…
    about 2 days ago
  • New post on Science and Enterprise: Univ. Labs Design, Produce Medical Face Shields #Science #Business
    about 2 days ago
  • An analysis of health care spending by large employers shows both companies and their employees are saving money fr…
    about 2 days ago

Please share Science & Enterprise

Sanofi, VCs Back Start-Up Deriving Natural Product Drugs

DNA strand (NSF)

(James. J. Caras, National Science Foundation)

The French drug maker Sanofi, with American venture capital (VC) companies Third Rock Ventures and Greylock Partners, are investing up to $125 million in Warp Drive Bio a new biotechnology company in Cambridge, Massachusetts. Warp Drive Bio, being incubated at Third Rock Ventures, specializes in using genomics to derive drug candidates from natural sources, such as microbes.

Third Rock Ventures founded Warp Drive Bio with Harvard University chemical biologist Gregory Verdine. Also co-founding the company are Harvard geneticist George Church and University of California – San Francisco professor of pharmaceutical chemistry James Wells.

Warp Drive Bio is developing a technology based on genomics to create therapies targeting biological pathways. The technology would systematically uncover drug candidates based on genomic signatures of naturally occurring microbes. Sanofi will give Warp Drive Bio access to its strains library and natural product expertise. In return, Sanofi will be granted certain access rights to Warp Drive Bio’s technology and products.

“Prior to Warp Drive Bio, no one had created a comprehensive discovery engine that selectively mines from nature those products with transformative pharmaceutical potential,” says Verdine. “Warp Drive Bio has developed that capability and is using it to discover powerful next-generation drugs that target the central circuitry of human cells in completely new ways.”

The investors plan to provide up to $75 million in equity and an additional $50 million in initial capital to move Warp Drive Bio’s technology to the proof-of-concept stage. Sanofi also retains an option to acquire Warp Drive Bio if certain milestones are met. The five-year deal does not preclude Warp Drive Bio from establishing other partnerships.

Read more:

*     *     *

Please share Science & Enterprise ...

Comments are closed.